Contact
searchSearch
HMP Global
Login

October 2016

Department

Research in Review
Pembrolizumab More Cost Effective Than Docetaxel for PD-L1-Positive NSCLC
10/31/2016
The associated improvement in survival and quality-adjusted life years (QALYs) makes pembrolizumab a more cost-effective option than docetaxel for patients with programmed death ligand 1 (PD-L1)-positive non-small...
The associated improvement in survival and quality-adjusted life years (QALYs) makes pembrolizumab a more cost-effective option than docetaxel for patients with programmed death ligand 1 (PD-L1)-positive non-small...
The...
10/31/2016
Journal of Clinical Pathways
Research in Review
MicroRNA a Novel Biomarker for Gastric Cancer
10/12/2016
Serum microRNA-206 (miRNA) may serve as not only a novel diagnostic biomarker for gastric cancer but also as an indicator of prognosis and cancer recurrence, according to a study published in Cellular Physiology...
Serum microRNA-206 (miRNA) may serve as not only a novel diagnostic biomarker for gastric cancer but also as an indicator of prognosis and cancer recurrence, according to a study published in Cellular Physiology...
...
10/12/2016
Journal of Clinical Pathways
Research in Review
Mixed Consensus on Cardiovascular Screening Guidelines
10/12/2016
Primary care physicians play an important role in the prevention of cardiovascular disease (CVD) but still find implementation of prevention strategies challenging, which may be limiting their usage. A review of...
Primary care physicians play an important role in the prevention of cardiovascular disease (CVD) but still find implementation of prevention strategies challenging, which may be limiting their usage. A review of...
...
10/12/2016
Journal of Clinical Pathways
Research in Review
Clinical Pathway Improves Screening and Treatment for Osteoporosis
10/12/2016
Despite the high frequency of osteoporosis, it is still underdiagnosed and undertreated in many health care settings. However, a group of Belgium researchers may have developed a clinical pathway capable of...
Despite the high frequency of osteoporosis, it is still underdiagnosed and undertreated in many health care settings. However, a group of Belgium researchers may have developed a clinical pathway capable of...
...
10/12/2016
Journal of Clinical Pathways
Feature
Measurements of Medication Adherence: In Search of a Gold Standard
10/12/2016
Eugene Kreys, PharmD, PhD, BCPS
Abstract: Poor medication adherence results in worse clinical outcomes and increased health care expenditures. Clinical pathways programs should address medication adherence to support the fundamental purpose of...
Abstract: Poor medication adherence results in worse clinical outcomes and increased health care expenditures. Clinical pathways programs should address medication adherence to support the fundamental purpose of...
...
10/12/2016
Journal of Clinical Pathways

Feature

From the Field
A Novel Case Management System to Address Patient-Identified Concerns in Hematology and Oncology Clinical Pathways
10/12/2016
Joleen Hubbard, MD; Angelina Tan; Katrina Croghan, MS; Juliana Perez Botero, MD; Briant Fruth; Deirdre Pachman, MD; Veronica Lafky; Jeff Sloan, PhD; Carrie Thompson, MD; Rahma Warsame, MD; Angela Dispenzieri, MD
Abstract: Modern clinical practice places restrictions on the amount of information communicated in a typical office visit, impeding patient concerns from being adequately addressed. A point-of-care case management...
Abstract: Modern clinical practice places restrictions on the amount of information communicated in a typical office visit, impeding patient concerns from being adequately addressed. A point-of-care case management...
...
10/12/2016
Journal of Clinical Pathways

Column

Pharma Insights
Formulary Exclusion Lists Create Challenges for Pharma and Payers Alike
10/12/2016
Larry Blandford, PharmD; Andrew Cournoyer, RPh, MBA
The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...
The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...
The...
10/12/2016
Journal of Clinical Pathways
Clinical Pathways GPS
The Future of Clinical Pathways: The Potential Impact of the Presidential Election
10/12/2016
Scott Guerin, PhD; Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Although the topic of health care will continue to be a political one, the continued growth of public health care spending suggests that the government will need to continue its shift toward improving the value of...
Although the topic of health care will continue to be a political one, the continued growth of public health care spending suggests that the government will need to continue its shift toward improving the value of...
...
10/12/2016
Journal of Clinical Pathways

Insights

Interview
COA Speaks Out Against PBM Restrictions of Medication Access
10/12/2016
CVS Caremark®, one of the leading pharmacy benefit managers (PBMs) in the United States, recently made a decision to restrict patient access to physician dispensing of medication directly to patients at their...
CVS Caremark®, one of the leading pharmacy benefit managers (PBMs) in the United States, recently made a decision to restrict patient access to physician dispensing of medication directly to patients at their...
CVS...
10/12/2016
Journal of Clinical Pathways
Interview
Pathways for Cancer Survivors
10/12/2016
Thanks to advances in medical research and more sophisticated methods of administration, cancer patients today are living longer than ever.1 Yet, while these advances have been universally celebrated by all health...
Thanks to advances in medical research and more sophisticated methods of administration, cancer patients today are living longer than ever.1 Yet, while these advances have been universally celebrated by all health...
...
10/12/2016
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

October 2016 Volume 2

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use